ACCREDITATION

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada and accredited by the Canadian Association for the Study of the Liver. Participants can claim up to a maximum of 6 study credits.

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at here.

PROGRAM AT A GLANCE
2:15 PM - 2:30 PMJoint ILCA-AASLD-CASL SymposiumStrategies for HCC prevention, including in non-viral liver diseaseGeorge Ioannou
2:30 PM - 2:45 PMJoint ILCA-AASLD-CASL SymposiumEmerging approaches to HCC surveillanceAmit Singal
2:45 PM - 3:00 PMJoint ILCA-AASLD-CASL SymposiumPrecision surveillance: close to reality?Neehar Parikh
3:00 PM - 3:15 PMJoint ILCA-AASLD-CASL SymposiumRecall systems and linkage to care: Important steps after surveillanceMaria Reig
3:15 PM - 3:30 PMJoint ILCA-AASLD-CASL SymposiumSystem- and population-level approaches to prevention and surveillanceJordan Feld
4:30 PM - 4:45 PMOpening Remarks from CASL President Carla Coffin
4:45 PM - 5:00 PMOpening Remarks from Canadian Liver Foundation Jennifer Nebesky
5:00 PM - 5:30 PMKeynote Speaker LectureState of the Art: Towards an AI-Driven Precision Medicine approach in Hepatocellular CarcinomaJulien Calderaro
5:30 PM - 7:30 PMWelcome Reception + Networking  
9:00 AM - 9:15 AMEpidemiology/Diagnosis/StagingEpidemiology: The burden of HCC in CanadaHélène Castel
9:20 AM - 9:50 AMEpidemiology/Diagnosis/StagingDiagnostic: The best modality to diagnose HCCStephanie Wilson
9:50 AM - 10:05 AMEpidemiology/Diagnosis/StagingStaging: Utility of the BCLC staging systemRobert Grant
10:05 AM - 10:20 AMEpidemiology/Diagnosis/StagingAdvances in Multidisciplinary Tumor Board Rounds (MTBR)Mayur Brahmania
10:20 AM - 10:30 AMEpidemiology/Diagnosis/StagingQ&A 
10:30 AM - 11:00 AMCoffee Break  
11:00 AM - 11:15 AMEarly & Intermediate HCCSurgery as first line therapyChaya Shwaartz
11:15 AM - 11:30 AMEarly & Intermediate HCCHow/When/Why liver transplant for HCCGonzalo Sapisochin
11:30 AM - 11:45 AMEarly & Intermediate HCCThe role of SBRT in HCC managementMichael Lock
11:45 AM - 12:00 PMEarly & Intermediate HCCThe role of LRT in HCC cureDavid Liu
12:00 PM - 12:15 PMEarly & Intermediate HCCQ&A 
12:15 PM - 1:15 PMLunch Break  
1:15 PM - 1:30 PMLate HCC & Palliative CarePrognostic Value of HCC Pathology 
1:30 PM - 1:45 PMLate HCC & Palliative CareHow to use IO therapyAnna Saborowski
1:45 PM - 2:00 PMLate HCC & Palliative CareUse of biomarker in predicting response to treatmentArndt Vogel
2:00 PM - 2:15 PMLate HCC & Palliative CareUtility of Palliative Care in HCC care. When is too early? 
2:15 PM - 2:30 PMLate HCC & Palliative CareQ&A 
2:30 PM - 3:00 PMAfternoon Break  
3:00 PM - 3:15 PMFuture DirectionsThe Importance and Impact of Cancer Research in CanadaJim Woodgett
3:15 PM - 3:30 PMFuture DirectionsHow to incorporate the patient voice in HCC careAndrea Wilson Woods
3:30 PM - 3:45 PMFuture DirectionsThe future of AI in HCCMamatha Bhat
4:00 PM - 4:15 PMFuture DirectionsQ&A 
4:15 PM - 4:30 PMClosing Remarks Mamatha Bhat
Mayur Brahmania